A Long-Term, Prospective, Observational, Registry of Patients With Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated With Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT)

ReclutandoClinicalTrials.gov

ID: NCT05966467Tipo: OBSERVATIONALInicio: 1 de feb de 2024Fin estimado: 1 de mar de 2030

Traducción no disponible, mostrando original

Resumen

Long-term, multicenter, multinational, observational, registry of patients with AQP4+ NMOSD that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT). The registry will also collect data on patient reported outcomes (PROs), quality of life (QoL), and targeted AQP4+ NMOSD therapies used to provide evidence on the real-world impact of ALXN-C5IT on patients with AQP4+ NMOSD.

Descripción detallada

At the time of enrollment in the Registry, participant records will be queried for retrospective information about the participant's medical history and AQP4+ NMOSD treatment history for the time period beginning 1 year prior to ALXN-C5IT initiation through Registry enrollment. The duration of data collection for the Registry will be approximately 5 years from the day the last participant is enrolled.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Participant is ≥ 18 years of age at the time of enrollment in the Registry.
Participant must have a confirmed diagnosis of AQP4+ NMOSD.
At the time of enrollment in the Registry, participants must be receiving treatment with ALXN-C5IT for the purpose of chronic relapse prevention in a manner consistent with the local label. Specifically, they should have received at least 1 dose of eculizumab within 4 weeks prior to enrollment or at least 1 dose of ravulizumab within 12 weeks prior to enrollment.
Participants must have both the following historical data available to be enrolled in the Registry: ALXN-C5IT dosing information since initiation and number and types of relapses from 1 year prior to ALXN-C5IT initiation through Registry enrollment.

Criterios de exclusión

Participants currently enrolled in an interventional clinical study for the treatment of AQP4+ NMOSD in which the intervention is a drug.

Ubicaciones

Clinical Trial Site

Buenos Aires, Argentina

Pablo Lopez

RECRUITING

Clinical Trial Site

Buenos Aires, Argentina

Daniel Munoz, MD

NOT_YET_RECRUITING

Clinical Trial Site

Buenos Aires, Argentina

Andres Villa, MD

RECRUITING

Clinical Trial Site

Buenos Aires, Argentina

Veronica Tkachuk

RECRUITING

Patrocinadores

PrincipalAlexion Pharmaceuticals, Inc.

Contactos

Alexion Pharmaceuticals, Inc. (Sponsor)

CONTACT

clinicaltrials@alexion.com 1-855-752-2356

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

A Long-Term, Prospective, Observational, Registry of Pati... | EligiMed